IP Library Granted Patent US 9,856,239
Granted Patent B1
US 9,856,239 · App. 15/723,785 · Granted Jan 2, 2018

Carboxylic acid compound, method for preparation thereof, and use thereof

Inventor: Yueheng Jiang (Shanghai, CN)
Assignee: InventisBio Shanghai Ltd.
C07D405/10C07B59/002C07C323/63C07D213/57C07D213/68C07D213/70C07D213/74C07D401/04C07B2200/05C07C2601/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,856,239
App. No.
15/723,785
Granted
Jan 2, 2018
Kind
B1
Abstract

The present invention relates to the technical field of medicine, and specifically relates to the carboxylic acid compound represented by the chemical formula I or chemical formula II, and a pharmaceutically acceptable salt, a prodrug, and a solvate thereof, and a method for preparation thereof, as well as a pharmaceutical composition containing the described substances, and a use thereof.

Claims (45)

1. A compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising the carboxylic acid compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A method of treating gout in a human, comprising administering to the human an effective amount of a compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

14. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

15. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

16. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

17. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

18. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

19. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

20. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

21. The method of claim 12 , comprising administering to the human an effective amount of compound

or a pharmaceutically acceptable salt thereof.

22. A method of reducing the blood uric acid level in a human, comprising administering to the human an effective amount of a compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

23. A method of treating hyperuricemia in a human, comprising administering to the human an effective amount of a compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

Assignments (3)
CHANGE OF NAME Recorded Feb 16, 2021
From: INVENTISBIO SHANGHAI LTD.
To: INVENTISBIO CO., LTD.
Reel/Frame 055313/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2017
From: JIANG, YUEHENG
To: SHANGHAI SHALETECH TECHNOLOGY, CO., LTD
Reel/Frame 044263/0247 →
CHANGE OF NAME Recorded Nov 30, 2017
From: SHANGHAI SHALETECH TECHNOLOGY CO., LTD
To: INVENTISBIO SHANGHAI LTD.
Reel/Frame 045356/0172 →
Priority Claims (1)
CN 2014 1 0398333 · Aug 13, 2014 · national
Continuity (1)
Continuation 15501387